Phase III trial of ruxolitinib in graft-versus-host disease meets primary endpoint

In the Phase III REACH3 trial, ruxolitinib was associated with a higher overall response rate than best available therapy at week 24 in patients with moderate or severe steroid-refractory or steroid dependent disease [no specific results reported].

SPS commentary:

An EU filing for ruxolitinib for acute graft-versus-host disease is planned for 2021. Results from the REACH3 study are due for presentation at an upcoming medical congress. 


Biospace Inc.